Home » Authors » Brady Huggett

Articles by Brady Huggett

RenaMed Forms Deal With Genzyme For Up To $43M

Sep. 29, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Kereos Raises $19.5M To Both Detect, Treat Disease

Sep. 20, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Caliper Adding Size Through $22M NovaScreen Purchase

Sep. 9, 2005

By Brady Huggett

Angry Merck Jurors Point To Public's Distaste For Pharma

Sep. 2, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

With Discovery Firms Worth Nothing,' Is Biotech Troubled?

Aug. 12, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Dyax's Phase I, II DX-88 Data Raise Hopes For Pivotal Trial

July 1, 2005

By Brady Huggett

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...